Literature DB >> 29949489

Metastasis-free Survival - A New End Point in Prostate Cancer Trials.

Julia A Beaver1, Paul G Kluetz1, Richard Pazdur1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29949489     DOI: 10.1056/NEJMp1805966

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Authors:  John Esther; Benjamin L Maughan; Neysi Anderson; Neeraj Agarwal; Andrew W Hahn
Journal:  Curr Treat Options Oncol       Date:  2019-02-11

2.  Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?

Authors:  Joseph A Sparano; N Lynn Henry
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

Review 3.  Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Authors:  Zaina T Al-Salama
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

4.  Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials.

Authors:  Melania Rivano; Luca Cancanelli; Lorenzo Di Spazio; Daniele Mengato; Marco Chiumente; Andrea Messori
Journal:  World J Urol       Date:  2022-09-09       Impact factor: 3.661

Review 5.  Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.

Authors:  Tristen Head; Nathaniel C Cady
Journal:  Exp Biol Med (Maywood)       Date:  2022-01-28

Review 6.  An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed?

Authors:  Nathan I Cherny
Journal:  Nat Rev Clin Oncol       Date:  2022-04-28       Impact factor: 65.011

Review 7.  Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.

Authors:  Fred Saad; Martin Bögemann; Kazuhiro Suzuki; Neal Shore
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-08       Impact factor: 5.455

8.  A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.

Authors:  Juan M Arriaga; Sukanya Panja; Mohammed Alshalalfa; Junfei Zhao; Min Zou; Arianna Giacobbe; Chioma J Madubata; Jaime Yeji Kim; Antonio Rodriguez; Ilsa Coleman; Renu K Virk; Hanina Hibshoosh; Onur Ertunc; Büşra Ozbek; Julia Fountain; R Jeffrey Karnes; Jun Luo; Emmanuel S Antonarakis; Peter S Nelson; Felix Y Feng; Mark A Rubin; Angelo M De Marzo; Raul Rabadan; Peter A Sims; Antonina Mitrofanova; Cory Abate-Shen
Journal:  Nat Cancer       Date:  2020-10-19

9.  The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer.

Authors:  Maria De Santis; Thomas Steuber
Journal:  ESMO Open       Date:  2019-04-12

10.  Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial.

Authors:  Rajnish Nagarkar; Darshana Patil; Timothy Crook; Vineet Datta; Sagar Bhalerao; Sonal Dhande; Vijay Palwe; Shirsendu Roy; Prakash Pandit; Ashwini Ghaisas; Raymond Page; Harjeetsingh Kathuria; Ajay Srinivasan; Dadasaheb Akolkar
Journal:  Oncotarget       Date:  2019-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.